Targeted prodrug approaches for hormone refractory prostate cancer

Medicinal Research Reviews

Volumn 35, Issue 3, 2015, Pages 554-585

  Aloysius, Herve ^a   Hu, Longqin ^a,b,c  

^a RUTGERS UNIVERSITY   (United States)

^b SHANXI MEDICAL UNIVERSITY   (China)

^c RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

Author keywords

Antibody directed enzyme prodrug therapy; Gene directed enzyme prodrug therapy; Prodrug design; Prostate specific antigen; Prostate specific membrane antigen

Indexed keywords

CHLORMETHINE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITHELIAL CELL ADHESION MOLECULE; FLOXURIDINE; GASTRIN RELEASING PEPTIDE RECEPTOR; NITRIC OXIDE; PACLITAXEL; PRODRUG; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; PROTOXIN; THAPSIGARGIN; TRANSCRIPTION FACTOR; TUMOR ANTIGEN; VINBLASTINE; ANTINEOPLASTIC AGENT;

ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; ENZYME ACTIVITY; ENZYME SPECIFICITY; GENE DIRECTED ENZYME PRODRUG THERAPY; HUMAN; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DEGRADATION; PROTEIN EXPRESSION; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DRUG THERAPY; MALE; METABOLISM; PROCEDURES; PROSTATIC NEOPLASMS; RECURRENT DISEASE;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DOXORUBICIN; DRUG THERAPY; HUMANS; MALE; NITRIC OXIDE; PACLITAXEL; PRODRUGS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECURRENCE; THAPSIGARGIN; VINBLASTINE;

EID: 84926443698     PISSN: 01986325     EISSN: 10981128     Source Type: Journal    
DOI: 10.1002/med.21333     Document Type: Article

References (195)

1. Brawley OW. Prostate cancer epidemiology in the United States. World J Urol 2012;30:195-200.
2. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. Cancer J Clin 2014;64:9-29.
3. NCI Surveillance Epidemiology and End Results (SEER) Program. Cancer statistics review, 1975-2010, based on November 2012 SEER data submission, posted to the SEER web site, 2013. http://seer.cancer.gov/csr/1975_2010/.
4. O'Keefe RJ, Guise TA. Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res 2003;415(suppl):S100-S104.
5. Roodman GD. Mechanisms of bone metastasis. New Engl J Med 2004;350:1655-1664.
6. Knudsen BS, Vasioukhin V. Mechanisms of prostate cancer initiation and progression. Adv Cancer Res 2010;109:1-50.
7. Akaza H, Hinotsu S, Usami M, Arai Y, Kanetake H, Naito S, Hirao Y. Combined androgen blockade with bicalutamide for advanced prostate cancer. Cancer 2009;115:3437-3445.
8. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD. Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide. Prostate Cancer Prostatic Dis 1999;2:4-8.
9. Dijkman GA, Janknegt RA, De Reijke TM, Debruyne FMJ. Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. J Urol 1997;158:160-163.
10. Beardsley E, Hotte S, North S, Ellard S, Winquist E, Kollmannsberger C, Mukherjee S, Chi K. A phase II study of sorafenib in combination with bicalutamide in patients with chemotherapy-naive castration resistant prostate cancer. Invest New Drugs 2012;30:1652-1659.
11. Scher HI, Liebertz C, Kelly WK, Mazumdar M, Brett C, Schwartz L, Kolvenbag G, Shapiro L, Schwartz M. Bicalutamide for advanced prostate cancer: The natural versus treated history of disease. J Clin Oncol 1997;15:2928-2938.
12. Scher HI, Beer TM, Higano CS, Anand A, Taplin M-E, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1-2 study. Lancet 2010;375:1437-1446.
13. Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, Wit RD, Mulders P, Hirmand M, Selby B, Bono JSD. Effect of MDV3100, an androgen receptor signaling inhibitor (ARSI), on overall survival in patients with prostate cancer postdocetaxel: Results from the phase III AFFIRM study. J Clin Oncol 2012;30(Suppl 5), abstr LBA1.
14. Attard G, Reid AHM, A'Hern R, Parker C, Oommen NB, Folkerd E, Messiou C, Molife LR, Maier G, Thompson E, Olmos D, Sinha R, Lee G, Dowsett M, Kaye SB, Dearnaley D, Kheoh T, Molina A, de Bono JS. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009;27:3742-3748.
15. Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008;26:4563-4571.
16. Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin M-E, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer. J Clin Oncol 2010;28:1496-1501.
17. Reid AHM, Attard G, Danila DC, Oommen NB, Olmos D, Fong PC, Molife LR, Hunt J, Messiou C, Parker C, Dearnaley D, Swennenhuis JF, Terstappen LWMM, Lee G, Kheoh T, Molina A, Ryan CJ, Small E, Scher HI, de Bono JS. Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate. J Clin Oncol 2010;28:1489-1495.
18. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI. Abiraterone and increased survival in metastatic prostate cancer. New Engl J Med 2011;364:1995-2005.
19. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 2011;71:6503-6513.
20. Efstathiou E, Titus M, Tsavachidou D, Tzelepi V, Wen S, Hoang A, Molina A, Chieffo N, Smith LA, Karlou M, Troncoso P, Logothetis CJ. Effects of abiraterone acetate on androgen signaling in castrate-resistant prostate cancer in bone. J Clin Oncol 2012;30:637-643.
21. Robson M, Dawson, N. How is androgen-dependent metastatic prostate cancer best treated? Hematol Oncol Clin North Am 1996;10:727-747.
22. Knudsen KE, Penning TM. Partners in crime: Deregulation of AR activity and androgen synthesis in prostate cancer. Trends Endocrinol Metabol 2010;21:315-324.
23. Mizokami A, Koh E, Fujita H, Maeda Y, Egawa M, Koshida K, Honma S, Keller ET, Namiki M. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 2004;64:765-771.
24. Shiota M, Yokomizo A, Naito S. Increased androgen receptor transcription: A cause of castration-resistant prostate cancer and a possible therapeutic target. J Mol Endocrinol 2011;47:R25-R41.
25. Tindall D, Lonergan P. Androgen receptor signaling in prostate cancer development and progression. J Carcinog 2011;10:20.
26. Fizazi K, Carducci M, Smith M, DamiÃo R, Brown J, Karsh L, Milecki P, Shore N, Rader M, Wang H, Jiang Q, Tadros S, Dansey R, Goessl C. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet 2011;377:813-822.
27. Kantoff PW, Schuetz TJ, Blumenstein BA, Michael Glode L, Bilhartz DL, Wyand M, Manson K, Panicali DL, Laus R, Schlom J, Dahut WL, Arlen PM, Gulley JL, Godfrey WR. Overall survival analysis of a phase II randomized controlled trial of a poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:1099-1105.
28. Daly ME, Makris A, Reed M, Lewis CE. Hemostatic regulators of tumor angiogenesis: A source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003;95:1660-1673.
29. Yu EM, Jain M, Aragon-Ching JB. Angiogenesis inhibitors in prostate cancer therapy. Discov Med 2010;10:521-530.
30. Ning YM, Gulley JL, Arlen PM, Woo S, Steinberg SM, Wright JJ, Parnes HL, Trepel JB, Lee MJ, Kim YS, Sun H, Madan RA, Latham L, Jones E, Chen CC, Figg WD, Dahut WL. Phase II trial of bevacizumab, thalidomide, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer. J Clin Oncol 2010;28:2070-2076.
31. Kelly WK, Halabi S, Carducci M, George D, Mahoney JF, Stadler WM, Morris M, Kantoff P, Monk JP, Kaplan E, Vogelzang NJ, Small EJ. Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401. J Clin Oncol 2012;30:1534-1540.
32. Gohji K, Kitazawa S, Tamada H, Katsuoka Y, Nakajima M. Expression of endothelin receptor A associated with prostate cancer progression. J Urol 2001;165:1033-1036.
33. Khan MA, Partin AW. Endothelin-A receptor antagonists and advanced prostate cancer. Rev Urol 2004;6:47-48.
34. Nelson JB, Fizazi K, Miller K, Higano C, Moul JW, Akaza H, Morris T, McIntosh S, Pemberton K, Gleave M. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer 2012;118:5709-5718.
35. Lewington VJ, McEwan AJ, Ackery DM, Bayly RJ, Keeling DH, Macleod PM, Porter AT, Zivanovic MA. A prospective, randomised double-blind crossover study to examine the efficacy of strontium-89 in pain palliation in patients with advanced prostate cancer metastatic to bone. Eur J Cancer Clin Oncol 1991;27:954-958.
36. Oosterhof GON, Roberts JT, de Reijke TM, Engelholm SA, Horenblas S, von der Maase H, Neymark N, Debois M, Collette L. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: A phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. Eur Urol 2003;44:519-526.
37. Sartor O, Reid RH, Hoskin PJ, Quick DP, Ell PJ, Coleman RE, Kotler JA, Freeman LM, Olivier P. Samarium-153-Lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology 2004;63:940-945.
38. Tu SM, Millikan RE, Mengistu B, Delpassand ES, Amato RJ, Pagliaro LC, Daliani D, Papandreou CN, Smith TL, Kim J, Podoloff DA, Logothetis CJ. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate: A randomised phase II trial. Lancet 2001;357:336-341.
39. Guénard D, Guéritte-Voegelein F, Potier P. Taxol and taxotere: Discovery, chemistry, and structure-activity relationships. Acc Chem Res 1993;26:160-167.
40. Nicolaou KC, Dai WM, Guy RK. Chemistry and biology of taxol. Angew Chem Intl Ed Eng 1994;33:15-44.
41. Gravis G, Fizazi K, Joly Lobbedez F, Oudard S, Priou F, Latorzeff I, Delva R, Krakowski I, Laguerre B, Rolland F, Zanetta S. Survival analysis of a randomized phase III trial comparing androgen deprivation therapy (ADT) plus docetaxel versus ADT alone in hormone-sensitive metastatic prostate cancer (GETUG-AFU 15/0403). Ann Oncol 2012;23(Suppl 9), abstr. 8930.
42. Berthold DR, Pond GR, Soban F, De Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 2008;26:242-245.
43. Tannock IF, De Wit R, Berry WR, Horti J, Pluzanska A, Chi KN, Oudard S, Théodore C, James ND, Turesson I, Rosenthal MA, Eisenberger MA. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. New Engl J Med 2004;351:1502-1512.
44. Kelly WK, Curley T, Slovin S, Heller G, McCaffrey J, Bajorin D, Ciolino A, Regan K, Schwartz M, Kantoff P, George D, Oh W, Smith M, Kaufman D, Small EJ, Schwartz L, Larson S, Tong W, Scher H. Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer. J Clin Oncol 2001;19:44-53.
45. Oh WK, George DJ, Tay MH. Response to docetaxel/carboplatin in patients with hormone-refractory prostate cancer not responding to taxane-based chemotherapy. Clin Prostate Cancer 2005;4:61-64.
46. Regan MM, O'Donnell EK, Kelly WK, Halabi S, Berry W, Urakami S, Kikuno N, Oh WK. Efficacy of carboplatin-taxane combinations in the management of castration-resistant prostate cancer: A pooled analysis of seven prospective clinical trials. Ann Oncol 2010;21:312-318.
47. Amato RJ, Sarao H. A phase I study of paclitaxel/doxorubicin/thalidomide in patients with androgen- independent prostate cancer. Clin Genitourin Cancer 2006;4:281-286.
48. Petrylak DP. The treatment of hormone-refractory prostate cancer: Docetaxel and beyond. Rev Urol 2006;8:S48-S55.
49. Tannock IF, Osoba D, Stockler MR, Ernst DS, Neville AJ, Moore MJ, Armitage GR, Wilson JJ, Venner PM, Coppin CM, Murphy KC. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 1996;14:1756-1764.
50. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON. Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998;95:1735-1740.
51. Gao X, Luo Y, Wang Y, Pang J, Liao C, Lu H, Fang Y. Prostate stem cell antigen-targeted nanoparticles with dual functional properties: In vivo imaging and cancer chemotherapy. Int J Nanomed 2012;7:4037-4051.
52. Wu H, Shi H, Zhang H, Wang X, Yang Y, Yu C, Hao C, Du J, Hu H, Yang S. Prostate stem cell antigen antibody-conjugated multiwalled carbon nanotubes for targeted ultrasound imaging and drug delivery. Biomaterials 2014;35:5369-5380.
53. Mukherjee S, Richardson AM, Rodriguez-Canales J, Ylaya K, Erickson HS, Player A, Kawasaki ES, Pinto PA, Choyke PL, Merino MJ, Albert PS, Chuaqui RF, Emmert-Buck MR. Identification of EpCAM as a molecular target of prostate cancer stroma. Am J Pathol 2009;175:2277-2287.
54. Tai W, Mahato R, Cheng K. The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 2010;146:264-275.
55. Cornelio D, Roesler R, Schwartsmann G. Gastrin-releasing peptide receptor as a molecular target in experimental anticancer therapy. Ann Oncol 2007;18:1457-1466.
56. Dubuc C, Langlois R, Bénard F, Cauchon N, Klarskov K, Tone P, van Lier JE. Targeting gastrin-releasing peptide receptors of prostate cancer cells for photodynamic therapy with a phthalocyanine-bombesin conjugate. Bioorg Med Chem Lett 2008;18:2424-2427.
57. Bignami GS, Senter PD, Grothaus PG, Fischer KJ, Humphreys T, Wallace PM. N-(4'-hydroxyphenylacetyl)palytoxin: A palytoxin prodrug that can be activated by a monoclonal antibody-penicillin G amidase conjugate. Cancer Res 1992;52:5759-5764.
58. Vrudhula VM, Senter PD, Fischer KJ, Wallace PM. Prodrugs of doxorubicin and melphalan and their activation by a monoclonal antibody-penicillin-G amidase conjugate. J Med Chem 1993;36:919-923.
59. Kerr DE, Senter PD, Burnett WV, Hirschberg DL, Hellstrom I, Hellstrom KE. Antibody-penicillin-V-amidase conjugates kill antigen-positive tumor cells when combined with doxorubicin phenoxyacetamide. Cancer Immunol Immunother 1990;31:202-206.
60. Pedone E, Searle F, Brocchini S. Diethylstilbestrol glutamate as a potential substrate for ADEPT. J Drug Target 2006;14:437-443.
61. Hao XK, Liu JY, Yue QH, Wu GJ, Bai YJ, Yin Y. In vitro and in vivo prodrug therapy of prostate cancer using anti-γ-Sm-scFv/hCPA fusion protein. Prostate 2006;66:858-866.
62. Alaoui AE, Saha N, Schmidt F, Monneret C, Florent JC. New Taxol® (paclitaxel) prodrugs designed for ADEPT and PMT strategies in cancer chemotherapy. Bioorg Med Chem 2006;14:5012-5019.
63. Sahin U, Hartmann F, Senter P, Pohl C, Engert A, Diehl V, Pfreundschuh M. Specific activation of the prodrug mitomycin phosphate by a bispecific anti-CD30/anti-alkaline phosphatase monoclonal antibody. Cancer Res 1990;50:6944-6948.
64. 2-lactamase conjugates. J Med Chem 1997;40:2788-2792.
65. Atwell GJ, Boyd M, Palmer BD, Anderson RF, Pullen SM, Wilson WR, Denny WA. Synthesis and evaluation of 4-substituted analogues of 5-[N, N-bis(2-chloroethyl)amino]-2-nitrobenzamide as bioreductively activated prodrugs using an Escherichia coli nitroreductase. Anti-Cancer Drug Des 1996;11:553-567.
66. Senter PD, Springer CJ. Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates. Adv Drug Del Rev 2001;53:247-264.
67. Sharma SK, Bagshawe KD, Begent RHJ. Advances in antibody-directed enzyme prodrug therapy. Curr Opin Investig Drugs 2005;6:611-615.
68. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: Current status and future prospects. Prostate 2004;61:332-353.
69. Sayed Y, Taxel P. The use of estrogen therapy in men. Curr Opin Pharmacol 2003;3:650-654.
70. Scherr D, Pitts WR, Jr, Vaughan ED, Jr. Diethylstilbesterol revisited: Androgen deprivation, osteoporosis and prostate cancer. J Urol 2002;167:535-538.
71. Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RHJ. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours. Br J Cancer 2002;87:600-607.
72. Napier MP, Sharma SK, Springer CJ, Bagshawe KD, Green AJ, Martin J, Stribbling SM, Cushen N, O'Malley D, Begent RHJ. Antibody-directed enzyme prodrug therapy: Efficacy and mechanism of action in colorectal carcinoma. Clin Cancer Res 2000;6:765-772.
73. Aghi M, Hochberg F, Breakefield XO. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-164.
74. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther 1995;2:235-244.
75. Greco O, Dachs GU. Gene directed enzyme/prodrug therapy of cancer: Historical appraisal and future prospectives. J Cell Physiol 2001;187:22-36.
76. Singhal S, Kaiser LR. Cancer chemotherapy using suicide genes. Surg Oncol Clin North Am 1998;7:505-536.
77. Smythe WR. Prodrug/drug sensitivity gene therapy: Current status. Curr Oncol Rep 2000; 2:17-22.
78. Russell PJ, Kathri A. Novel gene-directed enzyme prodrug therapies against prostate cancer. Exp Opin Invest Drugs 2006;15:947-961.
79. Vajda A, Marignol L, Foley R, Lynch TH, Lawler M, Hollywood D. Clinical potential of gene-directed enzyme prodrug therapy to improve radiation therapy in prostate cancer patients. Cancer Treat Rev 2011;37:643-654.
80. Green NK, Youngs DJ, Neoptolemos JP, Friedlos F, Knox RJ, Springer CJ, Anlezark GM, Michael NP, Melton RG, Ford MJ, Young LS, Kerr DJ, Searle PF. Sensitization of colorectal and pancreatic cancer cell lines to the prodrug 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB1954) by retroviral transduction and expression of the E. coli nitroreductase gene. Cancer Gene Ther 1997;4:229-238.
81. Knox RJ, Friedlos F, Jarman M, Roberts JJ. A new cytotoxic, DNA interstrand crosslinking agent, 5-(aziridin-1-yl)-4-hydroxylamino-2-nitrobenzamide, is formed from 5-(aziridin-1-yl)-2, 4-dinitrobenzamide (CB 1954) by a nitroreductase enzyme in walker carcinoma cells. Biochem Pharmacol 1988;37:4661-4669.
82. Palmer DH, Milner AE, Kerr DJ, Young LS. Mechanism of cell death induced by the novel enzyme-prodrug combination, nitroreductase/CB1954, and identification of synergism with 5-fluorouracil. Br J Cancer 2003;89:944-950.
83. Palmer DH, Mautner V, Mirza D, Oliff S, Gerritsen W, van der Sijp JR, Hubscher S, Reynolds G, Bonney S, Rajaratnam R, Hull D, Horne M, Ellis J, Mountain A, Hill S, Harris PA, Searle PF, Young LS, James ND, Kerr DJ. Virus-directed enzyme prodrug therapy: Intratumoral administration of a replication-deficient adenovirus encoding nitroreductase to patients with resectable liver cancer. J Clin Oncol 2004;22:1546-1552.
84. Djeha AH, Hulme A, Dexter MT, Mountain A, Young LS, Searle PF, Kerr DJ, Wrighton CJ. Expression of Escherichia coli B nitroreductase in established human tumor xenografts in mice results in potent antitumoral and bystander effects upon systemic administration of the prodrug CB1954. Cancer Gene Ther 2000;7:721-731.
85. Weedon SJ, Green NK, McNeish IA, Gilligan MG, Mautner V, Wrighton CJ, Mountain A, Young LS, Kerr DJ, Searle PF. Sensitisation of human carcinoma cells to the prodrug CB1954 by adenovirus vector-mediated expression of E. coli nitroreductase. Int J Cancer 2000;86:848-854.
86. Helsby NA, Ferry DM, Patterson AV, Pullen SM, Wilson WR. 2-Amino metabolites are key mediators of CB 1954 and SN 23862 bystander effects in nitroreductase GDEPT. Br J Cancer 2004;90:1084-1092.
87. Patel P, Young JG, Mautner V, Ashdown D, Bonney S, Pineda RG, Collins SI, Searle PF, Hull D, Peers E, Chester J, Wallace DM, Doherty A, Leung H, Young LS, James ND. A phase I/II clinical trial in localized prostate cancer of an adenovirus expressing nitroreductase with CB1984. Mol Ther 2009;17:1292-1299.
88. Wang XY, Martiniello-Wilks R, Shaw JM, Ho T, Coulston N, Cooke-Yarborough C, Molloy PL, Cameron F, Moghaddam M, Lockett TJ, Webster LK, Smith IK, Both GW, Russel PJ. Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus. Gene Ther 2004;11:1559-1567.
89. Martiniello-Wilks R, Wang XY, Voeks DJ, Dane A, Shaw JM, Mortensen E, Both GW, Russell PJ. Purine nucleoside phosphorylase and fludarabine phosphate gene-directed enzyme prodrug therapy suppresses primary tumour growth and pseudo-metastases in a mouse model of prostate cancer. J Gene Med 2004;6:1343-1357.
90. Yoshimura I, Ikegami S, Suzuki S, Tadakuma T, Hayakawa M. Adenovirus mediated prostate specific enzyme prodrug gene therapy using prostate specific antigen promoter enhanced by the Cre-loxP system. J Urol 2002;168:2659-2664.
91. Yoshimura I, Suzuki S, Tadakuma T, Hayakawa M. Suicide gene therapy on LNCaP human prostate cancer cells. Int J Urol 2001;8:S5-S8.
92. Singh PP, Joshi S, Russell PJ, Verma ND, Wang X, Khatri A. Molecular chemotherapy and chemotherapy: A new front against late-stage hormone-refractory prostate cancer. Clin Cancer Res 2011;17:4006-4018.
93. Biotech Equity Partners Pty Ltd. A phase I gene therapy study of FP253/Fludarabine for prostate cancer (FP253-GDEPT). http://www.clinicaltrials.gov/ct2/show/NCT00625430.
94. Yue QH, Hu XB, Yin Y, Su MQ, Cheng XD, Yang L, Zhou TC, Hao X. Inhibition of prostate cancer by suicide gene targeting the FCY1 and HSV-TK genes. Oncol Rep 2009;22:1341-1347.
95. Advantagene Inc. Phase 3 study of ProstAtak™ with standard radiation therapy for localized prostate cancer (PrTK03). http://www.clinicaltrials.gov/ct2/show/NCT01436968.
96. Shalev M, Kadmon DOV, Teh BS, Butler EB, Aguilar-Cordova E, Thompson TC, Herman JR, Adler HL, Scardino PT, Miles BJ. Suicide gene threrapy toxicity after multiple and repeat injections in patients with localized prostate cancer. J Urol 2000;163:1747-1750.
97. Ayala G, Satoh T, Li R, Shalev M, Gdor Y, Aguilar-Cordova E, Frolov A, Wheeler TM, Miles BJ, Rauen K, Teh BS, Butler EB, Thompson TC, Kadmon D. Biological response determinants in HSV-tk + ganciclovir gene therapy for prostate cancer. Mol Ther 2006;13:716-728.
98. Fujita T, Teh BS, Timme TL, Mai W-Y, Satoh T, Kusaka N, Naruishi K, Fattah EA, Aguilar-Cordova E, Butler EB, Thompson TC. Sustained long-term immune responses after in situ gene therapy combined with radiotherapy and hormonal therapy in prostate cancer patients. Int J Radiat Oncol Biol Phys 2006;65:84-90.
99. Dubowchik GM, Walker MA. Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol Ther 1999;83:67-123.
100. Afshar S, Asai T, Morrison SL. Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer. Mol Cancer Ther 2009;8:185-193.
101. Yang Y, Aloysius H, Inoyama D, Chen Y, Hu L. Enzyme-mediated hydrolytic activation of prodrugs. Acta Pharm Sin B 2011;1:143-159.
102. Chang SS, Reuter VE, Heston WDW, Bander NH, Grauer LS, Gaudin PB. Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res 1999;59:3192-3198.
103. Pinto JT, Heston WDW. Prostate specific membrane antigen, a unique glutamate carboxypeptidase: A review of recent findings. Prostate J 1999;1:15-26.
104. Pinto JT, Suffoletto BP, Berzin TM, Qiao CH, Lin S, Tong WP, May F, Mukherjee B, Heston WDW. Prostate-specific membrane antigen: A novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 1996;2:1445-1451.
105. Gregorakis AK, Holmes EH, Murphy GP. Prostate-specific membrane antigen: Current and future utility. Semin Urol Oncol 1998;16:2-12.
106. Warren P, Li L, Song W, Holle E, Wei Y, Wagner T, Yu X. In vitro targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus. Cancer Res 2001;61:6783-6787.
107. Uchida A, O'Keefe DS, Bacich DJ, Molloy PL, Heston WDW. In vivo suicide gene therapy model using a newly discovered prostate-specific membrane antigen promoter/enhancer: A potential alternative approach to androgen deprivation therapy. Urology 2001;58:132-139.
108. Leippe M, Andrä J, Müller-Eberhard HJ. Cytolytic and antibacterial activity of synthetic peptides derived from amoebapore, the pore-forming peptide of Entamoeba histolytica. Proc Natl Acad Sci USA 1994;91:2602-2606.
109. Holle L, Song W, Holle E, Nilsson J, Wei Y, Li J, Wagner T, Yu X. In vivo targeted killing of prostate tumor cells by a synthetic amoebapore helix 3 peptide modified with two γ-linked glutamate residues at the COOH terminus. Mol Med Rep 2009;2:399-403.
110. Mhaka A, Gady AM, Rosen DM, Lo KM, Gillies SD, Denmeade SR. Use of methotrexate-based peptide substrates to characterize the substrate specificity of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2004;3:551-558.
111. Yagoda A, Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer 1993;71:1098-1109.
112. Davidson GA, Varhol RJ. Kinetics of thapsigargin-Ca2+-ATPase (sarcoplasmic reticulum) interaction reveals a two-step binding mechanism and picomolar inhibition. J Biol Chem 1995;270:11731-11734.
113. Furuya Y, Lundmo P, Short AD, Gill DL, Isaacs JT. The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigarin. Cancer Res 1994;54:6167-6175.
114. Lin XS, Denmeade SR, Cisek L, Isaacs JT. Mechanism and role of growth arrest in programmed (apoptotic) death of prostatic cancer cells induced by thapsigargin. Prostate 1997;33:201-207.
115. Denmeade SR, Mhaka AM, Rosen DM, Brennen WN, Dalrymple S, Dach I, Olesen C, Gurel B, DeMarzo AM, Wilding G, Carducci MA, Dionne CA, Møller JV, Nissen P, Christensen SB, Isaacs JT. Engineering a prostate-specific membrane antigen-activated tumor endothelial cell prodrug for cancer therapy. Sci Transl Med 2012;4:1-21.
116. Chang SS, O'Keefe DS, Bacich DJ, Reuter VE, Heston WDW, Gaudin PB. Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res 1999;5:2674-2681.
117. Israeli RS, Powell CT, Corr JG, Fair WR, Heston WDW. Expression of the prostate-specific membrane antigen. Cancer Res 1994;54:1807-1811.
118. Silver DA, Pellicer I, Fair WR, Heston WDW, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997;3:81-85.
119. GenSpera Inc. Study of G-202 as second-line therapy following Sorafenib in hepatocellular carcinoma (G-202-003). http://clinicaltrials.gov/show/NCT01777594.
120. GenSpera Inc. Efficacy, safety and CNS exposure of G-202 in patients with recurrent or progressive glioblastoma. http://clinicaltrials.gov/show/NCT02067156.
121. Mahalingam D, Wilding G, Denmeade S, Sarantopoulas J, Cosgrove D, Cetnar J, Azad N, Bruce J, Kurman M, Carducci M. 601 A first-in-human, Phase 1 clinical study of the safety, tolerability and pharmacokinetics (PK) of G-202, a Thapsigargin-based PSMA-activated prodrug, in patients with advanced solid tumors. Eur J Cancer 2012;48(Suppl 6):184-185.
122. GenSpera Inc. Phase 2 study of G-202 in patients with chemotherapy-naïve metastatic castrate-resistant prostate cancer. http://www.clinicaltrials.gov/ct2/show/NCT01734681.
123. Herschman JD, Smith DS, Catalona WJ. Effect of ejaculation on serum total and free prostate-specific antigen concentrations. Urology 1997;50:239-243.
124. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol 1995;154:407-413.
125. Balk SP, Ko Y-J, Bubley GJ. Biology of prostate-specific antigen. J Clin Oncol 2003;21:383-391.
126. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL. Measurement of prostrate-specific antigen in serum as a screening test for prostrate cancer. New Engl J Med 1991;324:1156-1161.
127. Diamandis E. New diagnostic applications and physiological functions of prostate specific antigen. Scand J Clin Lab Invest 1995;55:105-112.
128. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate 2007;67:312-329.
129. Culig Z, Hobisch A, Cronauer MV, Radmayr C, Trapman J, Hittmair A, Bartsch G, Klocker H. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-1, keratinocyte growth factor and epidermal growth factor. Eur Urol 1995;27:45-47.
130. Iwamura M, Sluss PM, Casamento JB, Cockett ATK. Insulin-Like growth factor I: Action and receptor characterization in human prostate cancer cell lines. Prostate 1993;22:243-252.
131. Cramer SD, Chen Z, Peehl DM. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: Inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 1996;156:526-531.
132. 2-2 by primary prostatic epithelial cells and its activation by prostate-specific antigen. J Cell Physiol 2005;202:361-370.
133. Iwamura M, Hellman J, Cockett ATK, Lilja H, Gershagen S. Alteration of the hormonal bioactivity of parathyroid hormone-related protein (PTHrP) as a result of limited proteolysis by prostate-specific antigen. Urology 1996;48:317-325.
134. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Investig 1985;76:1899-1903.
135. Malm J, Hellman J, Hogg P, Lilja H. Enzymatic action of prostate-specific antigen (PSA or hK3): Substrate specificity and regulation by Zn2+, a tight-binding inhibitor. Prostate 2000;45:132-139.
136. Ménez R, Michel S, Muller BH, Bossus M, Ducancel F, Jolivet-Reynaud C, Stura EA. Crystal structure of a ternary complex between human prostate-specific antigen, its substrate acyl intermediate and an activating antibody. J Mol Biol 2008;376:1021-1033.
137. Michel S, Collomb-Clerc E, Geourjon C, Charrier JP, Passagot J, Courty Y, Deleage G, Jolivet-Reynaud C. Selective recognition of enzymatically active prostate-specific antigen (PSA) by anti-PSA monoclonal antibodies. J Mol Recognit 2005;18:225-235.
138. Denmeade SR, Sokoll LJ, Chan DW, Khan SR, Isaacs JT. Rapid communication: Concentration of enzymatically active prostate-specific antigen (PSA) in the extracellular fluid of primary human prostate cancers and human prostate cancer xenograft models. Prostate 2001;48:1-6.
139. Leinonen J, Zhang W, Stenman U. Complex formation between PSA isoenzymesand protease inhibitors. J Urol 1996;155:1099-1103.
140. Otto A, Bar J, Birkenmeier G. Prostate specific antigen forms complexes with human α2-macroglobulin and binds to the α2-macroglobulin receptor/ldl receptor-related protein. J Urol 1998;159:297-303.
141. Denmeade SR, Lou W, Lovgren J, Malm J, Lilja H, Isaacs JT. Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen. Cancer Res 1997;57:4924-4930.
142. Garsky VM, Lumma PK, Feng DM, Wai J, Ramjit HG, Sardana MK, Oliff A, Jones RE, DeFeo-Jones D, Freidinger RM. The synthesis of a prodrug of doxorubicin designed to provide reduced systemic toxicity and greater target efficacy. J Med Chem 2001;44:4216-4224.
143. DeFeo-Jones D, Garsky VM, Wong BK, Feng DM, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Wai J, Senderak ET, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Freidinger R, Huff J, Oliff A, Jones RE. A peptide-doxorubicin prodrug activated by prostate-specific antigen selectively kills prostate tumor cells positive for prostate-specific antigen in vivo. Nat Med 2000;6:1248-1252.
144. Denmeade SR, Nagy A, Gao J, Lilja H, Schally AV, Isaacs JT. Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen. Cancer Res 1998;58:2537-2540.
145. Denmeade SR, Jakobsen CM, Janssen S, Khan SR, Garrett ES, Lilja H, Christensen SB, Isaacs JT. Prostate-specific antigen-activated thapsigargin prodrug as targeted therapy for prostate cancer. J Natl Cancer Inst 2003;95:990-1000.
146. Kumar SK, Williams SA, Isaacs JT, Denmeade SR, Khan SR. Modulating paclitaxel bioavailability for targeting prostate cancer. Bioorg Med Chem 2007;15:4973-4984.
147. Jakobsen CM, Denmeade SR, Isaacs JT, Gady A, Olsen CE, Christensen SB. Design, synthesis, and pharmacological evaluation of thapsigargin analogues for targeting apoptosis to prostatic cancer cells. J Med Chem 2001;44:4696-4703.
148. Tang X, Xian M, Trikha M, Honn KV, Wang PG. Synthesis of peptide-diazeniumdiolate conjugates: Towards enzyme activated antitumor agents. Tetrahedron Lett 2001;42:2625-2629.
149. Williams SA, Merchant RF, Garrett-Mayer E, Isaacs JT, Buckley TJ, Denmeade SR. A prostate-specific antigen-activated channel-forming toxin as therapy for prostatic disease. J Natl Cancer Inst 2007;99:376-385.
150. Mhaka A, Denmeade SR, Yao W, Isaacs JT, Khan SR. A 5-fluorodeoxyuridine prodrug as targeted therapy for prostate cancer. Bioorg Med Chem Lett 2002;12:2459-2461.
151. Jiang Y, DiPaola RS, Hu L. Synthesis and stereochemical preference of peptide 4-aminocyclophosphamide conjugates as potential prodrugs of phosphoramide mustard for activation by prostate-specific antigen (PSA). Bioorg Med Chem Lett 2009;19:2587-2590.
152. Jiang Y, Hu, L. Phenylalanyl-aminocyclophosphamides as model prodrugs for proteolytic activation: Synthesis, stability, and stereochemical requirements for enzymatic cleavage. Bioorg Med Chem Lett 2007;17:517-521.
153. Jones GB, Mitchell MO, Weinberg JS, D'Amico AV, Bubley GJ. Towards enzyme activated antiprostatic agents. Bioorg Med Chem Lett 2000;10:1987-1989.
154. Hu L, Wu X. Chemotherapeutic conjugates and methods of use. US Patent US20100075927 A1, 2007.
155. Brady SF, Pawluczyk JM, Lumma PK, Feng DM, Wai JM, Jones R, DeFeo-Jones D, Wong BK, Miller-Stein C, Lin JH, Oliff A, Freidinger RM, Garsky VM. Design and synthesis of a pro-drug of vinblastine targeted at treatment of prostate cancer with enhanced efficacy and reduced systemic toxicity. J Med Chem 2002;45:4706-4715.
156. DeFeo-Jones D, Brady SF, Feng DM, Wong BK, Bolyar T, Haskell K, Kiefer DM, Leander K, McAvoy E, Lumma P, Pawluczyk JM, Wai J, Motzel SL, Keenan K, Van Zwieten M, Lin JH, Garsky VM, Freidinger R, Oliff A, Jones RE. A prostate-specific antigen (PSA)-activated vinblastine prodrug selectively kills PSA-secreting cells in vivo. Mol Cancer Ther 2002;1:451-459.
157. DiPaola RS, Rinehart J, Nemunaitis J, Ebbinghaus S, Rubin E, Capanna T, Ciardella M, Doyle-Lindrud S, Goodwin S, Fontaine M, Adams N, Williams A, Schwartz M, Winchell G, Wickersham K, Deutsch P, Yao SL. Characterization of a novel prostate-specific antigen-activated peptide-doxorubicin conjugate in patients with prostate cancer. J Clin Oncol 2002;20:1874-1879.
158. Atkinson JM, Siller CS, Gill GH. Tumour endoproteases: The cutting edge of cancer drug delivery? . Br J Pharmacol 2008;153:1344-1352.
159. Spencer CM, Faulds D. Paclitaxel: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 1994;48:794-847.
160. Stein CA. Mechanisms of action of taxanes in prostate cancer. Semin Oncol 1999;26:3-7.
161. Wani MC, Taylor HL, Wall ME, Coggon P, McPhail AT. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 1971;93:2325-2327.
162. Hitt R, Paz-Ares L, Brandáriz A, Castellano D, Peña C, Millán JM, Calvo F, Ortiz de Urbina D, López E, Álvarez-Vicent JJ, Cortés-Funes H. Induction chemotherapy with paclitaxel, cisplatin and 5-fluorouracil for squamous cell carcinoma of the head and neck: Long-term results of a phase II trial. Ann Oncol 2002;13:1665-1673.
163. Perez EA. Paclitaxel in breast cancer. Oncologist 1998;3:373-389.
164. Cattaneo-Pangrazzi RMC, Schott H, Schwendener RA. In vivo activity of a PSA-activated doxorubicin prodrug against PSA-producing human prostate cancer xenografts. Prostate 2000;45:80-83.
165. Christensen SB, Andersen A, Kromann H, Treiman M, Tombal B, Denmeade S, Isaacs JT. Thapsigargin analogues for targeting programmed death of androgen-independent prostate cancer cells. Bioorg Med Chem 1999;7:1273-1280.
166. Garthwaite J, Charles SL, Chess-Williams R. Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intercellular messenger in the brain. Nature 1988;336:385-388.
167. Gillespie JS, Liu X, Martin W. The effects of L-arginine and N(G)-monomethyl L-arginine on the response of the rat anococcygeus muscle to NANC nerve stimulation. Br J Pharmacol 1989;98:1080-1082.
168. Hibbs JB, Jr, Taintor RR, Vavrin Z. Macrophage cytotoxicity: Role for L-arginine deiminase and imino nitrogen oxidation to nitrite. Science 1987;235:473-476.
169. Nathan CF, Hibbs JB, Jr. Role of nitric oxide synthesis in macrophage antimicrobial activity. Curr Opin Immunol 1991;3:65-70.
170. Wink DA, Vodovotz Y, Laval J, Laval F, Dewhirst MW, Mitchell JB. The multifaceted roles of nitric oxide in cancer. Carcinogenesis 1998;19:711-721.
171. Fitzhugh AL, Keefer LK. Diazeniumdiolates: Pro- and antioxidant applications of the 'NONOates'. Free Radic Biol Med 2000;28:1463-1469.
172. Keefer LK. Nitric oxide-releasing compounds: From basic research to promising drugs. Chemtech 1998;28:30-35.
173. Coombs GS, Bergstrom RC, Pellequer JL, Baker SI, Navre M, Smith MM, Tainer JA, Madison EL, Corey DR. Substrate specificity of prostate-specific antigen (PSA). Chem Biol 1998;5:475-488.
174. Jiang Y, Hu L. Peptide conjugates of 4-aminocyclophosphamide as prodrugs of phosphoramide mustard for selective activation by prostate-specific antigen (PSA). Bioorg Med Chem 2013;21:7507-7514.
175. Abrami L, Fivaz M, Van Der Goot FG. Adventures of a pore-forming toxin at the target cell surface. Trends Microbiol 2000;8:168-172.
176. Rossjohn J, Feil SC, McKinstry WJ, Tsernoglou D, Van Der Goot G, Buckley JT, Parker MW. Aerolysin-A paradigm for membrane insertion of beta-sheet protein toxins? J Struct Biol 1998;121:92-100.
177. Singh R, Browning JL, Abi-Habib R, Wong K, Williams SA, Merchant R, Denmeade SR, Buckley TJ, Frankel AE. Recombinant prostate-specific antigen proaerolysin shows selective protease sensitivity and cell cytotoxicity. Anti-Cancer Drugs 2007;18:809-816.
178. Denmeade SR, Egerdie B, Steinhoff G, Merchant R, Abi-Habib R, Pommerville P. Phase 1 and 2 studies demonstrate the safety and efficacy of intraprostatic injection of PRX302 for the targeted treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2011;59:747-754.
179. Sophiris Bio Corp. An open-label, multi-center, phase IIa trial of PRX302 treatment of patients with locally recurrent prostate cancer after primary radiation therapy. http://www.clinicaltrials.gov/ct2/show/NCT00686088.
180. Elhilali MM, Pommerville P, Yocum RC, Merchant R, Roehrborn CG, Denmeade SR. Prospective, randomized, double-blind, vehicle controlled, multicenter phase IIb clinical trial of the pore forming protein PRX302 for targeted treatment of symptomatic benign prostatic hyperplasia. J Urol 2012;189:1421-1426.
181. Sophiris Bio Corp. Randomized, double-blind, vehicle-controlled, multicenter safety and efficacy study of intraprostatic PRX302 for LUTS BPH (PLUS-1). http://www.clinicaltrials.gov/ct2/show/NCT01966614.
182. Santi DV, McHenry CS, Raines RT, Ivanetich KM. Kinetics and thermodynamics of the interaction of 5-fluoro-2′-deoxyuridylate with thymidylate synthase. Biochemistry 1987;26:8606-8613.
183. Hu L, Wu X, Han J, Chen L, Vass SO, Browne P, Hall BS, Bot C, Gobalakrishnapillai V, Searle PF, Knox RJ, Wilkinson SR. Synthesis and structure-activity relationships of nitrobenzyl phosphoramide mustards as nitroreductase-activated prodrugs. Bioorg Med Chem Lett 2011;21:3986-3991.
184. Shanafelt TD, Lin T, Geyer SM, Zent CS, Leung N, Kabat B, Bowen D, Grever MR, Byrd JC, Kay NE. Pentostatin, cyclophosphamide, and rituximab regimen in older patients with chronic lymphocytic leukemia. Cancer J 2007;109:2291-2298.
185. Korkmaz A, Topal T, Oter S. Pathophysiological aspects of cyclophosphamide and ifosfamide induced hemorrhagic cystitis; implication of reactive oxygen and nitrogen species as well as PARP activation. Cell Biol Toxicol 2007;23:303-312.
186. Brock N. The history of the oxazaphosphorine cytostatics. Cancer J 1996;78:542-547.
187. Wu X, Hu L. Efficient amidation from carboxylic acids and azides via selenatriazoline: Application to the coupling of amino acids and peptides with azides. J Org Chem 2007;72:765-774.
188. Wu X, Hu L. Amide bond formation from selenocarboxylates and aromatic azides. Tetrahedron Lett 2005;46:8401-8405.
189. Hortobagyi GN, Willey J, Rahman Z, Holmes FA, Theriault RL, Buzdar AU. Prospective assessment of cardiac toxicity during a randomized phase II trial of doxorubicin and paclitaxel in metastatic breast cancer. Semin Oncol 1997;24(suppl 17):65-68.
190. Weiss RB. The anthracyclines: Will we ever find a better doxorubicin? Semin Oncol 1992;19:670-686.
191. Xu X, Persson HL, Richardson DR. Molecular pharmacology of the interaction of anthracyclines with iron. Mol Pharmacol 2005;68:261-271.
192. DiPaola RS, Plante M, Kaufman H, Petrylak DP, Israeli R, Lattime E, Manson K, Schuetz T. A phase I trial of Pox PSA vaccines (PROSTVAC®-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM™) in patients with prostate cancer. J Transl Med 2006;4:1-5.
193. Desai RB, Schwartz MS, Matuszewski BK. The identification of three human metabolites of a peptide-doxorubicin conjugate using HPLC-MS-MS in positive and negative ionization modes. J Chromatogr Sci 2004;42:317-322.
194. Johnson IS. Historical background of Vinca alkaloid research and areas of future interest. Cancer Chemother Rep Pt 1 1968;52:455-461.
195. Wong BK, DeFeo-Jones D, Jones RE, Garsky VM, Feng DM, Oliff A, Chiba M, Ellis JD, Lin JH. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites. Drug Metab Dispos 2001;29:313-318.